BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that an abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2025 in Chicago.

BRANFORD, Conn., April 24, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. Azitra anticipates that this partnership will provide Azitra with a flexible source of funding, enabling the Company to progress its pipeline of live biotherapeutic precision products delivered topically to treat rare and severe dermatologic conditions. As Azitr

BRANFORD, Conn., March 12, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Chief Operating Officer, Travis Whitfill, Ph.D., MPH will present at the Microbiome Times Partnering Forum being held in Brussels, Belgium, March 18-19, 2025. Details of the presentation are as follows: Event: Microbiome Times Partnering Forum Location: Dome Eventhall, Brussels, Belgium Date/Time: Wednesday, March 19th, 4:25-4:35pm CET Title: Engineered S. Epidermidis for

BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

BRANFORD, Conn., Feb. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with certain institutional investor(s) to purchase 3,339,300 shares of common stock at an offering price of $0.2785 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $930.0 thousand before deducting placement agent fees and other offering expenses. This offering is expected to close on February 5, 2025, subject to customary closing conditions. Azitra intends to use the net pro

BRANFORD, Conn., Feb. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at the BIO CEO & Investor Conference being held February 10-11, 2025, in New York City. Details of the presentation are as follows: Event: BIO CEO & Investor Conference Date and Time:  February 10, 2025, at 3:45 p.m. ET Location: The New York Marriott Marquis, Royale Room Presenter: Travis Whitfill, Chief Operating Officer Registration: Link   During the

BRANFORD, Conn., Jan. 27, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, NJ. Details of the presentation are as follows: Event: The Microcap Conference Date and Time:  January 29, 2025, at 11:00 a.m., ET Location: Borgata Hotel Casino & Spa, Studio C, Atlantic City, NJ Presenter: Francisco Salva, Chief Executive Officer During the conference, m

BRANFORD, Conn., Jan. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of its previously announced public offering of 4,857,780 shares of common stock at a public offering price of $0.30 per share. The gross proceeds for the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses. This offering is expected to close on January 16, 2025, subject to customary closing conditions. Azitra intends to use the net proceeds of this offering for working capital and general corporate purposes.

BRANFORD, Conn., Jan. 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has commenced a public offering of shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares of common stock (or pre-funded warrants in lieu thereof) to be sold in the proposed offering will be sold by Azitra. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BRANFORD, Conn., Dec. 20, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at Biotech Showcase 2025 being held January 13-15, 2025 in San Francisco. Details of the presentation are as follows: Event: Biotech Showcase 2025 Date and Time:  January 13, 2025 at 3:00 p.m., PT Location: Hilton San Francisco Union Square (Yosemite C) Participant: Travis Whitfill, Chief Operating Officer Registration: Link   During the conference, memb

4 - Azitra, Inc. (0001701478) (Issuer)

BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the third quarter ended September 30, 2023. Q3 and Recent Business Highlights Advanced its pipeline programs including ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash) and its Joint Development Agreement with Bayer Completed and filed post-IND, FDA commitments for characterization of drug product for ATR-12 Selected and hired clinical research organization for ATR-12 clinical trial. Selected initial sites for activation Francisco Salva, Chief Executive Officer of Azitra, commented: "During t

8-K - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

10-K - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

424B5 - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

424B5 - Azitra, Inc. (0001701478) (Filer)

424B3 - Azitra, Inc. (0001701478) (Filer)

4 - Azitra, Inc. (0001701478) (Issuer)